Oceaneering International, Inc. (OII) announced on June 18 that the company was awarded a contract from Andarko Mocambique Area 1. Oceaneering will supply umbilicals, distribution hardware, and aftermarket services under the terms of the contract. OII provides engineered services and products for the global offshore energy industry. Sonal issued an alert about the event […]
On June 24, Krystal Biotech (KRYS) reported positive news from its Phase 2 clinical trial of KB103. The treatment was effective and well tolerated by patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). In addition, the FDA awarded Regenerative Medicine Advanced Therapy (RMAT) status to Krystal Biotech for KB103. Krystal Biotech is a gene therapy […]
Ziopharm Oncology (ZIOP) announced on June 11 that the FDA approved an investigational new drug (IND) application as part of a research and development project the company has with the National Cancer Institute. They will now begin clinical trials in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy that uses Ziopharm’s Sleeping Beauty platform. […]
The May 2019 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide
On June 6, La Jolla Pharmaceutical Company (LJPC) announced positive clinical trial results from its Phase 2 study of LJPC-401. This was a pre-specified interim analysis of its synthetic human hepcidin in patients with hereditary hemochromatosis (HH). Patients experienced statistically significant efficacy levels and tolerated the drug well. Sonal detected the news event and […]
Emergent BioSolutions Inc. (EBS) announced on June 3 that the company received a 10-year contract with the U.S. Department of Health and Human Services. Under the terms of the contract, Emergent BioSolutions will provide a continuous supply of Vaccinia Immune Globulin Intravenous (VIGIV) over the next ten years for $535 million. VIGIC is the only […]
Let us send you a summary of the signals Sonal generates EVERY WEEK… and you can decide if you’re missing anything.